{"id":"https://openalex.org/W4361953285","doi":"https://doi.org/10.1158/1078-0432.c.6529322.v1","title":"Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma","display_name":"Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361953285","doi":"https://doi.org/10.1158/1078-0432.c.6529322.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6529322.v1","doi":"https://doi.org/10.1158/1078-0432.c.6529322.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6529322.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6529322.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073906112","display_name":"Sant P. Chawla","orcid":"https://orcid.org/0000-0002-9522-6744","observed_orcids":["https://orcid.org/0000-0002-9522-6744"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sant P. Chawla","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029455802","display_name":"Sanjay Goel","orcid":"https://orcid.org/0000-0002-2798-7568","observed_orcids":["https://orcid.org/0000-0002-2798-7568"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sanjay Goel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2798-7568","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059734562","display_name":"Warren Allen Chow","orcid":"https://orcid.org/0000-0003-0889-5841","observed_orcids":["https://orcid.org/0000-0003-0889-5841"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Warren Chow","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104666966","display_name":"Fadi Braiteh","orcid":"https://orcid.org/0000-0003-2051-3893","observed_orcids":["https://orcid.org/0000-0003-2051-3893"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fadi Braiteh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043007782","display_name":"Arun S. Singh","orcid":"https://orcid.org/0000-0002-1633-7746","observed_orcids":["https://orcid.org/0000-0002-1633-7746"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arun S. Singh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059915005","display_name":"Juneko E. Grilley\u2010Olson","orcid":"https://orcid.org/0000-0002-1896-7020","observed_orcids":["https://orcid.org/0000-0002-1896-7020"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Juneko E. Grilley Olson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1896-7020","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070278638","display_name":"Atsushi Osada","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Atsushi Osada","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035582674","display_name":"Iulian Bobe","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Iulian Bobe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5077414729","display_name":"Richard F. Riedel","orcid":"https://orcid.org/0000-0001-5412-8710","observed_orcids":["https://orcid.org/0000-0001-5412-8710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard F. Riedel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5412-8710","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.8227999806404114,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.8227999806404114,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.12370000034570694,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.017799999564886093,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ph-sensitive-linker","display_name":"pH-sensitive linker","score":0.8149999976158142},{"id":"https://openalex.org/keywords/soft-tissue-sarcoma","display_name":"soft tissue sarcoma","score":0.8799999952316284},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7770000100135803},{"id":"https://openalex.org/keywords/metastatic-sarcoma","display_name":"metastatic sarcoma","score":0.6919999718666077},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7590000033378601},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.9679999947547913},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9409999847412109},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8130000233650208},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7860000133514404},{"id":"https://openalex.org/keywords/angiosarcoma","display_name":"angiosarcoma","score":0.824999988079071},{"id":"https://openalex.org/keywords/endometrial-stromal-sarcoma","display_name":"endometrial stromal sarcoma","score":0.9829999804496765},{"id":"https://openalex.org/keywords/enhanced-permeability-and-retention-effect","display_name":"enhanced permeability and retention effect","score":0.7639999985694885}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7627754211425781},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.636118471622467},{"id":"https://openalex.org/C2780835546","wikidata":"https://www.wikidata.org/wiki/Q425122","display_name":"Epirubicin","level":4,"score":0.6119129657745361},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5699421763420105},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4850303530693054},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.48261794447898865},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4786228537559509},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.4747876524925232},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4671318829059601},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35759711265563965},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.3007863163948059},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2733076214790344},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2665366232395172},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2380335032939911},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6529322.v1","doi":"https://doi.org/10.1158/1078-0432.c.6529322.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6529322.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6529322.v1","doi":"https://doi.org/10.1158/1078-0432.c.6529322.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6529322.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3022598503","https://openalex.org/W3168253271","https://openalex.org/W4361937040","https://openalex.org/W4361936930","https://openalex.org/W2568258136","https://openalex.org/W4361945602","https://openalex.org/W2764334703","https://openalex.org/W2588812426","https://openalex.org/W2587610481","https://openalex.org/W2005124630"],"abstract_inverted_index":{"AbstractPurpose:":[0],"NC-6300":[1,45,66,75,103,202,232],"is":[2],"a":[3,11,31,69,207],"novel":[4],"nanoparticle":[5],"formulation":[6],"of":[7,44,65,81,97,102,225],"epirubicin":[8,199,221],"that":[9],"has":[10],"pH-sensitive":[12],"linker":[13],"conjugated":[14],"to":[15,23,35,91,161],"epirubicin.":[16],"It":[17],"exhibits":[18],"selective":[19],"tumor":[20],"accumulation":[21],"owing":[22],"enhanced":[24],"permeability":[25],"and":[26,38,58,99,121,135,152,157,165,185,197,215],"retention":[27],"effect.":[28],"We":[29],"conducted":[30],"phase":[32,40,61],"1b":[33,62],"trial":[34,64],"determine":[36],"MTD":[37,156,214],"recommended":[39],"II":[41],"dose":[42,87],"(RP2D)":[43],"monotherapy":[46,67,104],"in":[47,173,183,194,230,236],"advanced,":[48],"metastatic,":[49],"or":[50],"unresectable":[51],"solid":[52,125,240],"tumors,":[53,241],"including":[54,242],"soft-tissue":[55,116],"sarcomas.":[56],"Patients":[57],"Methods:":[59],"This":[60],"dose-escalation":[63],"employed":[68],"Bayesian":[70],"continuous":[71],"reassessment":[72],"method":[73],"design.":[74],"was":[76,177,181,192,203,228],"administered":[77],"on":[78],"day":[79],"1":[80],"every":[82],"21-day":[83],"cycle,":[84],"with":[85,115,119,123,206,238],"epirubicin-equivalent":[86],"increments":[88],"from":[89],"125":[90],"215":[92],"mg/m2.":[93],"Safety,":[94],"efficacy,":[95],"quality":[96],"life,":[98],"pharmacokinetic":[100],"profile":[101],"were":[105,112,145,159],"evaluated.":[106],"Results:":[107],"Twenty-nine":[108],"subjects":[109],"(16":[110],"male)":[111],"enrolled:":[113],"17":[114],"sarcoma,":[117],"one":[118],"osteosarcoma,":[120],"11":[122],"other":[124],"tumors.":[126],"Observed":[127],"dose-limiting":[128],"toxicities":[129],"included":[130],"thrombocytopenia,":[131],"stomatitis,":[132],"lung":[133],"infection,":[134],"febrile":[136,153],"neutropenia.":[137],"The":[138,169],"most":[139],"common":[140],"grade":[141],"3/4":[142],"adverse":[143],"events":[144],"neutropenia":[146,154],"(59%),":[147],"anemia":[148],"(24%),":[149,151],"thrombocytopenia":[150],"(21%).":[155],"RP2D":[158,216],"determined":[160],"be":[162],"185":[163],"mg/m2":[164],"150":[166],"mg/m2,":[167],"respectively.":[168],"objective":[170],"response":[171,180],"rate":[172],"the":[174,213],"evaluable":[175],"population":[176],"11%.":[178],"Partial":[179],"observed":[182,193,229],"angiosarcoma":[184],"endometrial":[186],"stromal":[187],"sarcoma.":[188,243],"A":[189,223],"dose-dependent":[190],"increase":[191],"both":[195],"total":[196],"released":[198],"concentrations.":[200],"Conclusions:":[201],"well":[204],"tolerated":[205],"manageable":[208],"side":[209],"effect":[210],"profile,":[211],"despite":[212],"being":[217],"higher":[218],"than":[219],"conventional":[220],"doses.":[222],"signal":[224],"preliminary":[226],"activity":[227],"angiosarcoma.":[231],"warrants":[233],"further":[234],"investigation":[235],"patients":[237],"advanced":[239]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-05T00:00:00"}